Antitumor activity
tumor
DISEASE, TUMOR
Among the 20 treated patients, 17 (85%) were evaluable for efficacy due to having RECISTv1.1 measurable disease and having completed post-baseline tumor assessment by radiographic imaging studies or physician-determined clinical progression. Two patients withdrew from the study during the first cycle to seek other treatment options. One patient was deemed non-evaluable for follow-up tumor re-assessment due to lack of contrast in target lesions to accurately assess the response.Figure 